On the Record · Sinovac Biotech
Sinovac Biotech acquisitions, on the record
The businesses Sinovac Biotech bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Synermore Biologics (Suzhou) Co., Ltd.Word for word“In November 2023, SKY Biologics acquired 94.03% of the equity interest in Synermore Biologics (Suzhou) Co., Ltd., a company which focuses on the development and production of monoclonal antibody drugs in the fields of infectious diseases, malignant tumors and autoimmune diseases, with a consideration of RMB2,303.8 million.” 20-F for 2023 | acquisition | November 2023 | RMB2,303.8 million |
Tangshan YianWord for word“In January 2004, Sinovac Antigua entered into a share purchase agreement with Heping Wang and issued him 3.5 million of its common shares and a promissory note in the amount of $2.2 million to acquire from him a 100% equity interest in Tangshan Yian.” 20-F for 2023 | agreed acquisition | January 2004 | $2.2 million |
Synermore Biologics (Suzhou) Co., Ltd. (94.03% equity interest, acquired by SKY Biologics)Word for word“In November 2023, SKY Biologics acquired 94.03% of the equity interest in Synermore Biologics (Suzhou) Co., Ltd., a company which focuses on the development and production of monoclonal antibody drugs in the fields of infectious diseases, malignant tumors and autoimmune diseases, with a consideration of RMB2,303.8 million.” 20-F for 2024 | acquisition | In November 2023 | RMB2,303.8 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | — | $1.7 million | — |
| 2017-12-31 | — | $1.7 million | — |
| 2021-12-31 | $0 | — | — |
| 2022-12-31 | $0 | — | — |
| 2023-12-31 | $0 | — | — |
| 2024-12-31 | $100.2 million | — | $27.5 million |
| 2025-12-31 | $14.1 million | — | — |
Read from Sinovac Biotech’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-06-05. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.